Daré Bioscience, Inc.
Moat Score — Daré Bioscience, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Daré holds patents covering Ovaprene's proprietary knitted polymer barrier and spermicidal ring design plus FDA approval and orphan-style regulatory exclusivities for XACIATO, giving it defensible IP in a historically under-patented women's health niche. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small clinical-stage biotech with no manufacturing scale, Daré has no structural cost advantage versus larger pharmaceutical competitors and in fact faces higher per-unit R&D and trial costs than scaled players. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Daré does not control commercial pricing since XACIATO is licensed to Organon, and any future approved products would face similar partner-controlled pricing dynamics rather than independent pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in pharmaceutical development or sales; product value does not increase as more patients or prescribers adopt it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a physician and patient settle on a specific therapy like XACIATO for bacterial vaginosis, modest prescribing inertia exists, but low-cost generic alternatives mean switching costs are limited for cost-sensitive conditions. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Women's health drug development is not a naturally scale-limited niche in the way some specialty markets are, and larger pharmaceutical companies could enter if they chose to prioritize the category, limiting durable efficient-scale protection. |